Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
| ▸ | CD44 | P16070 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18455678 | 0.62 | PNMT (0.30) | PNMTCD44MAOB | |
| SCHEMBL14205193 | 0.60 | PNMT (0.33) | PNMTCD44MAOB | |
| SCHEMBL8279313 | 0.60 | PNMT (0.31) | PNMTCD44MAOB | |
| SCHEMBL23571534 | 0.59 | — | — | |
| SCHEMBL2500830 | 0.58 | PNMT (0.30) | PNMTCD44MAOB | |
| SCHEMBL2507795 | 0.58 | PNMT (0.31) | PNMTCD44MAOB | |
| SCHEMBL17734069 | 0.58 | PNMT (0.32) | PNMTCD44MAOB | |
| SCHEMBL20827730 | 0.58 | — | — | |
| SCHEMBL7260527 | 0.56 | — | — | |
| SCHEMBL1592783 | 0.55 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193744-B2 | Heterocyclic nuclear hormone receptor modulators | ABBVIE INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150297596-A1 | ISOXAZOLINES AS THERAPEUTIC AGENTS | ABBVIE INC. (US) | 2015-10-22 | — | — | US | disclosed |
| US-9150592-B2 | Heterocyclic nuclear hormone receptor modulators | ABBVIE INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9115151-B2 | Substituted 2,10-dihydro-9-oxa-1,2,4A-triazaphenanthren-3-ones and uses thereof | ABBVIE INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9029409-B2 | Isoxazolines as therapeutic agents | ABBVIE INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140206663-A1 | TRIAZINONE COMPOUNDS | WUXI APPTECH (SHANGHAI) CO., LTD. (CN) | 2014-07-24 | — | — | US | disclosed |
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2014089904-A1 | TRIAZINONE COMPOUNDS | ABBVIE INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20140162985-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20130023526-A1 | Isoxazolines as Therapeutic Agents | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| US-20120238549-A1 | Nuclear Hormone Receptor Modulators | ABBOTT LABORATORIES (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2011079105-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | NR5A2, NR5A1, GPER1 | PNMT 2232/4885CD44 2433/4885MAOB 3491/4885 |
| US-20150297596-A1 | ISOXAZOLINES AS THERAPEUTIC AGENTS | CYP3A7, CYP11B2, CYP11B1 | PNMT 2136/4885CD44 3451/4885MAOB 1423/4885 |
| US-20140206663-A1 | TRIAZINONE COMPOUNDS | THPO, IL5, CYP11B2 | PNMT 833/4885CD44 2727/4885MAOB 1560/4885 |
| US-20130023526-A1 | Isoxazolines as Therapeutic Agents | CYP3A7, CYP11B2, CYP11B1 | PNMT 2136/4885CD44 3451/4885MAOB 1423/4885 |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | PNMT 266/4885CD44 3880/4885MAOB 1555/4885 |
| US-20120238549-A1 | Nuclear Hormone Receptor Modulators | NR5A1, NR5A2, NR3C2 | PNMT 2085/4885CD44 2660/4885MAOB 4346/4885 |
| US-20140162985-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | NR5A2, NR5A1, GPER1 | PNMT 2232/4885CD44 2433/4885MAOB 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.